PPARG and airway hyperresponsiveness: They further reported that PPAR-γ activation using rosiglitazone or pioglitazone agonists or adenovirus carrying PPAR-γ cDNA could upregulate the expression levels of PTEN, which inactivated PI3K/Akt pathway to inhibit bronchial inflammation and airway hyperresponsiveness in OVA-induced asthmatic mice [29].